MedX issues 3.62 million units for $362,078 in debt
2013-07-19 16:58 ET - News Release
Mr. Steve Guillen reports
MEDX HEALTH CORP. ANNOUNCES SHARE ISSUANCE PURSUANT TO DEBT SETTLEMENT AGREEMENTS AND ALSO GRANT OF STOCK OPTIONS
Further to the notification given in the press release issued on July 4, 2013, MedX Health Corp. has issued 3,620,780 units, comprising a total of 3,620,780 common shares at a deemed value of 10 cents per share and 1,810,390 share purchase warrants, to settle outstanding debt of $362,078.16. Each share purchase warrant entitles the holder to purchase one (1) fully paid non-assessable common share from the treasury of MedX during the period commencing on the date of issue and expiring on December 31, 2015 (the "Expiration Date"), at an exercise price of $0.20 if exercised before January 1, 2015, and at an exercise price of $0.30 if exercised after December 31, 2014 and prior to the Expiration Date. The shares and securities underlying the share purchase warrants are subject to a restricted hold period of four months and one day from July 10, 2013.
Following issuance of these shares, the Company will have 44,966,291 common shares outstanding on an undiluted basis.
The Company also announces that the Board of Directors has approved the grant of 400,000 incentive stock options to a senior officer; the options are exercisable at $0.10 per share, vesting immediately and are valid for a period of five years expiring on July 15, 2018, and otherwise subject to the terms of the Company's Stock Option Plan.
About SIMSYS and MoleMate Skin Cancer Imaging
SIMSYS and MoleMate received approval from Health Canada, and is available for all Canadian physicians and dermatologist. SIMSYSA and MoleMateA is also FDA approved for use in the USA and is currently under review for CE approval for use in Europe, the UK, and Australia. For more information log onto: www.simsys-molemate.com and click on 'See More', and see approximately 2mm below the surface of suspicious moles and lesions with additional information and images related to every mole and lesions associated with all types of melanomas and non-melanomas. SIMSYSA and MoleMateA is an optical biopsy that uses patented technology that features a hand-held scanner device designed for clinical office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images in real-time for physicians and dermatologist to evaluate all types of moles or lesions within seconds, providing images that can reveal if a mole or lesion is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense. Physicians and dermatologist interested in learning more should contact MedX Health Corp. or log onto www.simsys-molemate.com.
We seek Safe Harbor.
|
Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.
Zurück geht es hier.
Thread abonnieren
